Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
- 9 February 2007
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (6) , 611-613
- https://doi.org/10.1200/jco.2006.09.3542
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2007
- A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast CancerJournal of Clinical Oncology, 2007
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non–Small-Cell Lung Cancer TumorsJournal of Clinical Oncology, 2006
- Cost-Effectiveness in a Flat World — Can ICDs Help the United States Get Rhythm?New England Journal of Medicine, 2005
- Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancerAnnals of Oncology, 2005
- When Will the U.S. Flinch at Cancer Drug Prices?JNCI Journal of the National Cancer Institute, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- Cost-Effectiveness And Evidence Evaluation As Criteria For Coverage PolicyHealth Affairs, 2004